Health Policy & Advocacy
Basic InformationMore InformationLatest News
Doctors May Be Overprescribing Opioids After SurgeriesMost Editors at Leading Medical Journals Are White, Study FindsAHA News: Why Everyone Should Care About Health Disparities – And What to Do About ThemUS to Send 500 Million COVID Vaccine Doses to Countries Desperate for ShotsThink You Can Skip That Annual Physical?  Think AgainYour Doctor Appointments Might Look Different Post-PandemicU.S. Blood Supply Is Safe From Coronavirus, Study FindsThink You Can Spot Fake News? Many Can'tTelehealth Is Growing in Use, Acceptance Among Americans: PollAHA News: Deep Disparities Persist in Who Gets Exposed to Secondhand SmokeMany Pre-Surgery Tests Are Useless, So Why Are Hospitals Still Using Them?U.S. Officials Say 50% of American Adults Are Now Fully VaccinatedMore Pot-Linked Poisoning Cases as Edibles' Popularity BoomsU.S. Issues Tough Travel Warnings for Japan Ahead of OlympicsScience Studies Most Likely to Be Wrong Are the Most Widely ReadFully Vaccinated Travelers Can Soon Visit EU CountriesAHA News: Research Into Asian American Health Doesn't Always Reflect Their DiversityIt's Still Tough to Find Prices on Most U.S. Hospital WebsitesGet First Colonoscopy at 45, not 50: U.S. Expert PanelMagnets in Cellphones, Smartwatches Might Affect Pacemakers, FDA WarnsAHA News: These 'Concrete Steps' Could Help Fight Racism in Health CareFear of Losing Health Insurance Keeps 1 in 6 U.S. Workers in Their JobsWhen Drug Companies Raise Prices, Patients' Out-of-Pocket Costs RiseMost Top U.S. Surgeons Are White and That's Not ChangingAmericans Missed Almost 10 Million Cancer Screenings During PandemicU.S. Birth Rates Continue to FallBiden Sets New Goal of Vaccinating 70% of Americans by July 41 in 3 Neighborhoods in Major U.S. Cities Is a 'Pharmacy Desert'You Got Your COVID Shot: What to Do With That Vaccine CardFinding a Doctor Is Tough and Getting Tougher in Rural AmericaUrgent Care or the ER? Which Should You Choose?FDA Poised to Ban Menthol CigarettesPoll Reveals Who's Most Vaccine-Hesitant in America and WhyAHA News: Food, Culture and the Secret Ingredient to Address Lack of Diversity in Nutrition FieldCDC Decision on Johnson & Johnson Vaccine Pause Expected FridayAHA News: How to Make Sure Everyone Gets a Fair Shot at the COVID-19 VaccineLittle Progress in Boosting Numbers of Black American DoctorsHigh-Profile Police Brutality Cases Harm Black Americans' Mental Health: StudyAHA News: Could the Pandemic Help Boost Diversity in Clinical Trials?Americans Still Avoiding ERs in Pandemic, But Uptick Seen in Mental Health CrisesCDC Panel Says It Needs More Time to Study J&J Vaccine Clotting CasesAHA News: 5 Things to Know This Earth Day About How the Environment Affects Health4 in 10 Adults Over 50 Consult Online Reviews When Picking a DoctorCBD or THC? Cannabis Product Labels Often Mislead, Study FindsPandemic Has Put Many Clinical Trials on HoldDespite Pandemic's Toll, Many Older Adults Don't Have Living Wills'Heart-in-a-Box' Can Be Lifesaving, Matching Up Distant Donors With PatientsPublic Lost Trust in CDC During COVID Crisis: PollNearly 8 in 10 School, Child Care Staff Have Gotten at Least 1 Dose of COVID Vaccine: CDCWhy Are ER Wait Times Getting Longer for Kids in Mental Health Crisis?
Related Topics

Health Insurance

When Drug Companies Raise Prices, Patients' Out-of-Pocket Costs Rise

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: May 6th 2021

new article illustration

THURSDAY, May 6, 2021 (HealthDay News) -- When prescription drug "list" prices go up, patients often take a hit in the wallet, a new study shows.

Researchers found that while some people are buffered against drug price hikes by their health insurance plan, many are not.

Those in plans that require co-insurance or a deductible for prescriptions typically watch their out-of-pocket expenses rise, according to the study.

Prescription list prices are akin to the sticker price on a car, explained lead researcher Dr. Benjamin Rome, of Brigham and Women's Hospital and Harvard Medical School, in Boston.

In the United States, drug companies can decide where a list price starts and how it increases over time. On average, research shows, those prices have increased by 9% each year over the past decade.

Drug manufacturers have argued that list prices "aren't important," Rome said.

That's because manufacturers often offer "rebates" to health insurance plans and pharmacy benefit managers that bring down a drug's net price.

However, Rome's team found those rebates are not shielding patients in many cases.

"We're shining a light on a problem that results from two forces," Rome said.

Rising list prices are one, he noted. The other is the trend for health insurance plans to add co-insurance and/or deductibles to patients' prescription drug coverage.

Co-insurance is the percentage of a health care cost that a patient must cover. So when a drug price goes up, so will the co-insurance.

A deductible, meanwhile, requires patients to foot their health care bills for a certain amount before their insurance coverage kicks in.

Traditionally, health plans required only flat co-payments for medications. So a decade ago, Rome said, many Americans may have been buffered against rising list prices.

The reality is different now, he noted.

In this study, more than half of patients had plans that required co-insurance and/or a deductible for prescription drugs.

The findings come from a national database including 30 million Americans with employer-sponsored health insurance between 2015 and 2017.

The researchers zeroed in on 79 brand-name drugs, finding that list prices typically increased by about 17% over the two-year period.

Overall, the study found, patients in plans that only required drug co-payments seemed to be "insulated" from those price increases.

That was not true of people in plans with co-insurance and deductibles. Their out-of-pocket expenses typically rose by 15%. (Half saw a greater increase, half a lesser one.) And those increases correlated with rising list prices.

In contrast, there was no correlation between patients' out-of-pocket expenses and the post-rebate net price of medications.

The findings were published online May 4 in JAMA Network Open.

Frederick Isasi is executive director of Families USA, a nonpartisan consumer health care advocacy group. He said, "These rebates happen behind the curtain, and the savings are not being passed on to consumers."

But to Isasi, who was not involved in the study, any solution has to go beyond passing rebates on to patients.

"We're seeing drug price increases that are far beyond inflation," Isasi said. And it's those unfettered and "irrational" hikes that are the root issue, he argued.

Not everyone sees it that way.

"The critical question left unanswered by this report is why insurance companies force patients to pay out-of-pocket costs tied to the full price of medicines, while these same insurance companies receive billions of dollars in manufacturer rebates," Sarah Sutton, a spokesperson for the trade group PhRMA, which represents the pharmaceutical industry, said in a statement.

"Nearly half of every dollar spent on medicines doesn't go to the innovative companies that discovered the medicines, but to middlemen, insurers, the government and other entities. This system is broken, and that's why we put forward solutions to lower what patients pay for prescription medicines, including changes that will ensure savings in the system are shared with patients at the pharmacy," Sutton added.

But Isasi said that while drug companies support such measures, they resist reforms that would cut into their profits.

"Any solution here has to address the fundamental issue of price," he said, noting that high drug prices also "get baked into" the monthly premiums people pay for insurance.

Rome agreed that "exorbitant" drug prices are the core issue. Some proposals by lawmakers include caps on list-price increases and penalties against companies that raise those prices above inflation, he noted.

Isasi said, "We know that a third of Americans have a hard time affording their medications." And that, he added, can lead to skipped doses, cutting pills in half and worsening health.

Rome described the system of price hikes and confidential rebates as "sort of a game."

"I don't want my patients, or any patients, to be caught in the middle," he said.

More information

The American Medical Association has more on prescription drug prices.

SOURCES: Benjamin Rome, MD, researcher, Program on Regulation, Therapeutics, and Law, Brigham and Women's Hospital, and instructor, medicine, Harvard Medical School, Boston; Frederick Isasi, JD, MPH, executive director, Families USA, Washington, D.C.; PhRMA, statement, May 2021; JAMA Network Open, May 4, 2021, online

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net